Loerop James 4

What Happened

• James Loerop, Chief Business Officer of Aclaris Therapeutics (ACRS), had 15,980 shares withheld by the company to satisfy tax withholding in connection with the vesting and settlement of restricted stock units (RSUs). The withholding was recorded at $2.48 per share for a total value of $39,630. This is a tax-withholding disposition (transaction code F), not an open-market sale or purchase.

Key Details

• Transaction date: 2025-02-01 (reported on amended Form 4 filed 2026-02-03).
• Price per share: $2.48; Total value: $39,630.
• Transaction code: F — shares withheld by issuer to satisfy tax withholding on RSU vesting.
• Amendment note: Filing includes an amendment (F2) correcting the number of shares withheld; this may change the reported beneficial ownership in subsequent filings.
• Shares owned after transaction: Not specified in the provided excerpt; the amendment notes the adjustment will affect subsequent reported beneficial ownership.
• Timeliness: The Form 4 was filed about a year after the transaction date (late), and an amendment was filed to correct the withheld-share count.

Context

• Withholding to cover taxes on vested RSUs is routine and does not indicate an insider selling shares on the open market; it simply satisfies tax obligations tied to equity compensation. Purchases or open-market sales carry more direct signals about insider sentiment.